Which Is Safest, Wegovy or Mounjaro? (October 2026)

01

Is Wegovy or Mounjaro safer? The honest answer

Neither is established as safer than the other. Wegovy (semaglutide 2.4mg) and Mounjaro (tirzepatide) are both licensed UK treatments for weight management, and both carry a similar set of cautions: stomach-related side effects are the day-to-day issue, and rarer serious problems such as pancreatitis and gallbladder disease need urgent attention.

Mounjaro activates two gut-hormone receptors, GIP and GLP-1, while Wegovy activates the GLP-1 pathway only.¹ In the first large head-to-head trial, tirzepatide produced greater average weight loss. The practical safety question is: which medicine suits your history, and which will you tolerate well enough to continue?

Stomach side effects are the most common reason people struggle with either medicine. In the STEP 1 trial, gastrointestinal side effects were reported by many people on Wegovy, and a minority stopped because of them. Mounjaro's own information also warns that severe vomiting or diarrhoea can cause dehydration. So tolerability matters for both, and it is the first thing a prescriber looks at when choosing between them.

02

Wegovy and Mounjaro safety factors compared

A table cannot tell you which suits you. A prescriber weighs your medical history, other medicines, previous GLP-1 experience and how well you tolerated treatment.

03

What to do if you are choosing between them

Start by being clear about your reason for asking. If you are new to GLP-1 treatment, the question is usually which one to begin with. If you are already on one and struggling, the question is whether to switch. Those need different answers, and switching is always a prescriber decision, never something to improvise at home.

For new patients, complete a free online consultation. A GPhC-registered prescriber reviews your answers, and if treatment is unsuitable your order is refunded automatically. Be thorough about pancreatitis, gallbladder problems, thyroid cancer history, kidney or liver conditions, pregnancy plans and any depression history. Those details, more than any headline comparison, determine which option is safer for you.

If your main worry is the likelihood of unpleasant effects rather than serious risk, our guide on which has fewer side effects goes deeper. Safety here means more than the headline risk: it includes choosing a regulated pharmacy and a prescriber-led plan.

Related guides: Which Is More Effective Mounjaro or Wegovy and Which is safer wegovy or mounjaro and Which is better mounjaro or wegovy and Are side effects worse on mounjaro or wegovy and Wegovy or mounjaro which has less side effects.

04 · What safest means

What 'safest' actually means for GLP-1 medicines

'Safest' is a bundle of questions, and it helps to separate them. Which medicine causes fewer unpleasant side effects? Which has fewer serious risks? Which is safer for someone with a particular health condition? Which is safer to stay on long term? Each can have a different answer, and no single trial answers them all.

The main piece of comparative evidence is the SURMOUNT-5 trial. It was designed to compare effectiveness between the two, not to rank safety. It tells us tirzepatide produced greater average weight loss than semaglutide 2.4mg, and it supports the statement that both are effective, licensed treatments.¹⁵ It does not show that one is safer. Anyone who quotes it as proof of better or worse safety is stretching it.

Both medicines are prescription-only and licensed by the UK regulator on the basis of safety and efficacy data. That is the baseline: neither is an experimental or unregulated product when obtained through a legitimate route. Mounjaro is a once-weekly pre-filled KwikPen.¹

The gradual ladder matters for safety because stomach side effects are linked to dose increases. Both medicines are designed to be started low and increased in steps, which gives your body time to adapt. A prescriber may also hold you at a lower dose if you are not coping. That flexibility is one of the most important safety tools available, and it applies to both products.

What you can do is ask your prescriber how each medicine fits your history, then begin at the lowest dose and monitor how you feel.

The short version: safety is mostly about the right person, the right dose, the right supervision and a genuine supply chain.

05 · Side effects compared

Side effects: what to expect on each medicine

Stomach-related effects are the main practical issue on both Wegovy and Mounjaro. These medicines slow how quickly the stomach empties and change appetite signals, so nausea, a feeling of fullness and bowel changes are an expected part of the early weeks for many people.¹

For Wegovy, the STEP 1 trial gives us exact figures. In STEP 1, gastrointestinal side effects were reported by 74.2% of people on semaglutide 2.4mg, compared with 47.9% on placebo.⁹ Also, 7.0% stopped treatment because of side effects, compared with 3.1% on placebo.⁹ Read that fairly: most people on Wegovy had some stomach effect, but only a small minority stopped for that reason. A placebo group also reported stomach symptoms, which is a reminder that not every symptom is caused by the drug.

For Mounjaro, the most common side effects, affecting more than 1 in 10 people, are nausea, diarrhoea, vomiting, constipation and abdominal discomfort. The key practical point is that severe vomiting or diarrhoea can cause dehydration, which can strain the kidneys, so you should keep fluids up and get medical help straight away if you cannot keep fluids down.¹

What reduces the risk of rough side effects on either medicine?

• Start at the lowest dose and step up only when your prescriber agrees.
• Eat smaller meals and stop eating when you feel full.
• Keep up fluids, especially if you have loose stools or vomiting.
• Tell your clinical team early if symptoms are not settling; a lower dose or slower step may help.

Everything on that list applies equally to both medicines. If you are comparing based on side effects alone, our dedicated page, are side effects worse on Mounjaro or Wegovy, looks at the question from the tolerability angle.

The honest answer is that it depends on the person. Some people sail through one medicine and struggle with the other, and the reverse is also true.

Report any suspected side effect through the MHRA Yellow Card scheme as well as telling your prescriber. Yellow Card reports help regulators monitor real-world safety for both medicines.¹⁹

06 · Serious risks

Serious side effects: when to seek help

Serious side effects are uncommon on both medicines, but they need urgent attention, and knowing the warning signs is part of using either safely. The Mounjaro information lists three situations in which you should seek immediate medical help.¹³

• Possible pancreatitis: severe, persistent stomach pain that may spread to your back, with or without vomiting — stop using Mounjaro and get medical help straight away.
• Possible gallbladder problems: pain in the upper right abdomen, fever or yellowing of the skin or eyes — get medical help straight away.
• Severe allergic reaction: swelling of the face or throat and difficulty breathing. Get medical help straight away.

Because Wegovy is also a GLP-1 medicine, you should read its leaflet and talk to your prescriber rather than assume the lists are identical.¹⁸ Treat any severe, persistent abdominal pain on either medicine as a reason to get medical help straight away.

If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar, which feels like shakiness, sweating or confusion. Your prescriber may need to adjust those other medicines.¹³ It is not a case of the medicines being forbidden together; it is a case of needing a dose review.

Many people ask whether a GLP-1 medicine can do permanent damage. Mounjaro is not known to damage the kidneys or liver directly. The practical risk is indirect, through dehydration after severe vomiting or diarrhoea.¹ Raise any pre-existing kidney, liver, gallbladder or pancreas problems at consultation.

A sensible habit is to know your own baseline. If you have had gallstones, pancreatitis or severe digestive disease in the past, say so clearly. These are exactly the history items that can tip a prescriber toward one medicine over the other, or toward no GLP-1 treatment at all. A genuine pharmacy consultation exists to catch them.

Finally, seek help early rather than late. For sudden severe pain, yellowing of the skin or eyes, or swelling of the face or throat, get medical help straight away.

07 · Who should avoid them

Who should avoid Mounjaro or Wegovy

Safety begins with suitability, and some people should not take these medicines at all. For Mounjaro, you should not take it if you are allergic to tirzepatide or any of its ingredients, and it should not be used during pregnancy or while trying to conceive.¹³ Mounjaro must not be used during pregnancy, and it should be stopped at least one month before trying to conceive. If you become pregnant during treatment, stop the medicine and tell your prescriber promptly. Your prescriber will take extra care, or may recommend against treatment, if you have a history of pancreatitis, severe gut or digestive disease, diabetic retinopathy, or gallbladder problems.¹³ Always share your full medical history and medicine list during consultation.

The thyroid is another topic that causes unnecessary worry. In rodent studies tirzepatide caused thyroid C-cell tumours; it is not known whether this applies to humans, and no increase has been shown in human trials.¹ As a precaution, tell your prescriber if you or a close relative have had medullary thyroid cancer or the inherited condition MEN 2, because they will weigh that in your assessment. Routine thyroid monitoring is not required for most people.¹ Wegovy has its own thyroid-related cautions in its product information, so the same family-history conversation applies whichever medicine you consider.¹⁸

On kidneys and liver, no dose adjustment is needed for mild to moderate kidney or liver impairment on Mounjaro, though people with severe impairment need individual prescriber assessment.¹ That is useful if you have a long-term condition, but it is not a reason to skip the conversation.

If you are checking whether you are suitable before deciding between brands, work through these points.

• Have you ever had pancreatitis or gallbladder disease?
• Is there any personal or family history of medullary thyroid cancer or MEN 2?
• Are you pregnant, breastfeeding, or planning a pregnancy?
• Do you have severe digestive disease or diabetic eye disease?
• Which prescription and over-the-counter medicines do you take, including insulin or a sulfonylurea?

The weight criteria also matter. Both medicines are licensed for adults who meet defined weight and health thresholds, with BMI thresholds of 27, 30, 35 and 40 kg/m² used in different contexts. Your prescriber will confirm which apply to you.

If anything on the list applies, it does not automatically rule you out. It means a prescriber should weigh your individual risk and benefit, which is the whole point of a clinician-led service rather than a scoring script. It also means you should be wary of any seller who is happy to supply either medicine without asking about your history.

08 · Mood and long term

Mood, mental health and long-term use

Regulators have looked specifically at whether GLP-1 medicines are linked to low mood or suicidal thoughts, and the evidence reviewed did not support a causal link. The EMA's safety committee reviewed the evidence and concluded in 2024 that it does not support a causal link, and the MHRA keeps this under continuous review.¹⁷ That reassurance applies to the class of GLP-1 medicines, so it is relevant to both Wegovy and Mounjaro.

If you have thoughts of harming yourself or ending your life, get help straight away. Call 999 or go to A&E if you are in immediate danger. In England you can call NHS 111 and choose the mental health option, any time. You can also call Samaritans free on 116 123, day or night. Tell your prescriber about any change in your mood while taking Mounjaro.

That said, any big change in weight, appetite and routine can affect how you feel. Tell your prescriber about any history of depression, and seek help promptly if your mood drops or you have distressing thoughts during treatment.¹⁷ That advice is not a hint that one medicine is riskier; it is sensible practice with either, since a dramatic change in eating can be emotionally significant.

On the long term, treatment is designed as a continuing plan rather than a short burst. Tirzepatide stays in the body for a long time after a final dose, taking roughly four to five weeks to clear the system, and there is no way to speed this up, and nothing needs doing while it clears.¹ That matters if you are changing medicines or planning pregnancy.

Why are people stopping Wegovy? Reasons vary: stomach side effects are one documented reason, since a minority of trial participants stopped because of them. Others stop because they want to try a different medicine, because of cost, or because their circumstances change. Stopping any GLP-1 medicine should be discussed with your prescriber, particularly if you plan to switch, because the safe way to change is a supervised one.

Beyond the scales, trials of tirzepatide showed average improvements in waist size, blood pressure, cholesterol and blood-sugar measures, and most participants with prediabetes returned to normal blood-sugar levels.² These are trial-average secondary outcomes, not promises. They explain why prescribers view weight management as health management rather than appearance, and why the benefit side of the risk-benefit balance matters when comparing the two medicines.

09 · Efficacy and risk

Weighing benefit against risk: what the trials show

A medicine's safety is always judged against its benefit, so it helps to know what each delivers. In the first large head-to-head trial (SURMOUNT-5), adults on tirzepatide lost on average 20.2% of body weight over 72 weeks versus 13.7% on semaglutide 2.4mg (Wegovy).¹⁵ Both are effective, licensed treatments; which suits you depends on your health profile, tolerance and prescriber advice, not the headline number alone.¹⁵

The SURMOUNT-5 detail helps show how big the difference was across people. In SURMOUNT-5, 751 adults took tirzepatide or semaglutide 2.4mg for 72 weeks. At least 10% of body weight was lost by 81.6% on tirzepatide vs 60.5% on semaglutide; at least 15% by 64.6% vs 40.1%; at least 20% by 48.4% vs 27.3%; at least 25% by 31.6% vs 16.1%. Average loss was 22.8 kg vs 15.0 kg.¹⁵

For Wegovy on its own, the STEP 1 trial remains the reference point. In the STEP 1 trial, adults on semaglutide 2.4mg (Wegovy) lost on average 14.9% of body weight over 68 weeks, compared with 2.4% on placebo.⁹ That is a substantial benefit by any standard. To put it in practical terms, for someone starting at 100 kg, that average would be a loss of about 15 kg, though individual results vary widely.

For Mounjaro, SURMOUNT-1 reported that people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² These are trial averages, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.

Why does this matter for safety?

Do not read these trial figures as a verdict on safety. Different trials ran for different lengths, enrolled different people and counted events differently, so only SURMOUNT-5 supports a direct comparison, and that comparison is about weight loss. If you want to weigh the effectiveness question more, see which is more effective and which is better for weight loss.

10 · Switching safely

Switching between Wegovy and Mounjaro safely

If one medicine is not suiting you, switching is a legitimate option, but it must be done under prescriber supervision. There is no licensed direct conversion between semaglutide and tirzepatide. Typically the previous medicine is stopped, a washout interval observed, and Mounjaro started at a dose your prescriber judges appropriate, often the 2.5mg starting dose, sometimes adjusted based on your history.¹ Never run two GLP-1 medicines together.

The reason to avoid doing it yourself is that doses do not translate neatly. A person on the top Wegovy dose of 2.4mg cannot simply pick an equivalent Mounjaro pen, because the two medicines act differently.

Equally important is what not to do. Mounjaro must not be combined with other GLP-1 medicines, unlicensed 'research' peptides (such as retatrutide, which has no UK licence), or compounded copies. These combinations have no safety data and no regulated supply chain. If something promises faster results outside a licensed pathway, that is the warning sign.¹

A related misunderstanding is Ozempic. Ozempic is semaglutide licensed for type 2 diabetes. It is not a UK weight-loss medicine, and prescribing it privately for weight loss is off-label. The licensed weight-management options are Mounjaro (tirzepatide) and Wegovy (semaglutide 2.4mg), so a regulated UK pharmacy will not supply Ozempic for weight loss.¹

Tablets are also in the picture. There is no tablet form of Mounjaro. Two GLP-1 weight-loss tablets are now licensed in the UK: Wegovy tablets (oral semaglutide, made by Novo Nordisk) and Foundayo (orforglipron, made by Eli Lilly). They are different medicines with their own dosing, eligibility checks and trial results, and both are prescription-only.²⁰²¹

'Natural GLP-1' supplements such as berberine are not medicines, are not regulated for this use and have no comparable trial evidence. Low-cost and easy to buy does not mean safe or effective. Tell your prescriber about any supplements you take.

11 · Buying safely in the UK

Getting treatment safely: NHS and private routes

The safest way to use either medicine is to obtain it through a regulated route with a real clinical assessment. On the NHS, Mounjaro is available, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴⁶ Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.

NHS access to Wegovy runs through specialist weight-management services; ask your GP.

If you choose private treatment, check the pharmacy. EverydayMeds is a GPhC-registered UK online pharmacy, registration 9012878, and you can verify it on the GPhC register.¹² Our Mounjaro comes through official LillyDirect supply direct from Eli Lilly's UK distribution, as genuine KwikPens. The safety value of a known supply chain is real, because counterfeit and unregulated products are a recognised risk, and the MHRA publishes alerts about them.⁷

Warning signs of an unsafe seller are easy to spot. Be cautious of anyone offering to supply without a consultation or prescription, anyone promising specific results, anyone selling 'research' peptides or compounded copies, and anyone with no verifiable regulator registration.

How ordering works with us:

• Free online consultation: a short health questionnaire, no charge and no obligation.
• Prescriber review: reviewed by a GPhC-registered prescriber. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full.
• Dispensing and dispatch: dispensed by our registered pharmacy, with same-day dispatch when ordered by 3pm.
• Delivery: free next-day tracked delivery in temperature-controlled, discreet packaging. Saturday delivery is £14.99.

Needles, a sharps bin and injection guidance are included with every order. Pens are kept in the fridge until first use, at 2–8°C, and an in-use pen is licensed for up to 30 days (not above 30°C) out of the fridge.¹³ Follow the pen's instructions for the injection itself.

Aftercare includes ongoing monthly reviews, dose titration and follow-up, plus side-effect support. Repeat orders re-check suitability, with no auto-shipping, which is a safety feature rather than an inconvenience. Support is available Monday to Friday, 9am to 5pm, by email, account chat or phone on 0333 207 0413.

This medicine is prescription-only, used alongside a reduced-calorie diet and increased physical activity, and individual results vary.